Skip to main content
IDXXIDEXX Laboratories, Inc.Sell5.5·$560.79+0.69%
Open full analysis

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $560.79 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Expensive valuation; Concentration risk — Supplier: Ortho-Clinical Diagnostics.

IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in... Read more

$560.79+10.0% A.UpsideScore 5.5/10#11 of 26 Diagnostics & Research
QualityF-score8 / 9FCF yield1.79%
Stop $528.71Target $616.95(analyst − 13%)A.R:R 1.7:1
Analyst target$709.14+26.5%14 analysts
$616.95our TP
$560.79price
$709.14mean
$470
$805

Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $560.79 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Expensive valuation; Concentration risk — Supplier: Ortho-Clinical Diagnostics. Chart setup: Death cross but MACD improving, RSI 53. Score 5.5/10, moderate confidence.

Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-11
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Aug 3, 202653d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Wide economic moat
Risks
Concentration risk — Supplier: Ortho-Clinical Diagnostics
Expensive valuation
Below 200-day MA

Key Metrics

P/E (TTM)41.0
P/E (Fwd)33.7
Mkt Cap$43.9B
EV/EBITDA29.0
Profit Mgn24.6%
ROE72.9%
Rev Growth14.3%
Beta1.54
DividendNone
Rating analysts22

Quality Signals

Piotroski F8/9MoatWideCompounder

Options Flow

P/C1.86bearish
IV48%normal
Max Pain$430-23.3% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierOrtho-Clinical Diagnostics
    10-K Item 1: 'We are obligated to purchase all of our requirements for our current menu of Catalyst chemistry slides from Ortho to the extent Ortho is able to supply those requirements'

Material Events(8-K, last 90d)

  • 2026-03-26Item 5.02MEDIUM
    EVP Nimrata Hunt mutually agreed to cease as EVP Global Strategy and Commercial effective April 13, 2026, with advisory services through July 13, 2026. No named replacement for the role; no disagreement cited.
    SEC filing →
  • 2026-02-13Item 5.02LOW
    Director M. Anne Szostak notified IDEXX of her intention to retire from the Board effective immediately following the 2026 Annual Meeting (May 12, 2026). No disagreement with company cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Pe
3.0
Forward Pe
3.3
Peg Ratio
3.4
Ps
3.5
Analyst Target
6.0
Forward P/E: 33.7xPEG: 3.57
GatesMomentum 4.2<4.5Death cross (50MA < 200MA)Executive change: officer departure/appointmentA.R:R 1.7 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 53d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
53 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $527.12Resistance $581.47

Price Targets

$529
$617
A.Upside+10.0%
A.R:R1.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 4.2 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-03 (53d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IDXX stock a buy right now?

Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $560.79 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Expensive valuation; Concentration risk — Supplier: Ortho-Clinical Diagnostics. Chart setup: Death cross but MACD improving, RSI 53. Prior stop was $528.71. Score 5.5/10, moderate confidence.

What is the IDXX stock price target?

Take-profit target: $616.95 (+10.0% upside). Prior stop was $528.71. Stop-loss: $528.71.

What are the risks of investing in IDXX?

Concentration risk — Supplier: Ortho-Clinical Diagnostics; Expensive valuation; Below 200-day MA.

Is IDXX overvalued or undervalued?

IDEXX Laboratories, Inc. trades at a P/E of 41.0 (forward 33.7). TrendMatrix value score: 3.4/10. Verdict: Sell.

What do analysts say about IDXX?

22 analysts cover IDXX with a consensus score of 4.0/5. Average price target: $709.

What does IDEXX Laboratories, Inc. do?IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments,...

IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in 2025, with highly recurring revenue from consumables and subscriptions sold direct to veterinarians in the U.S. and internationally.

Related stocks: SHC (Sotera Health Company) · A (Agilent Technologies, Inc.) · WAT (Waters Corporation) · MEDP (Medpace Holdings, Inc.) · LH (Labcorp Holdings Inc.)
Home Stocks IDXX

Latest news

Latest News

GuruFocus47d ago
MSN47d ago
The Globe and Mail47d agoAnalyst
MarketBeat47d ago
MarketBeat48d ago
Insider Monkey19d agoProduct
Stock Titan26d ago
Yahoo Finance26d agoProduct
Traders Union34d ago
GuruFocus34d ago
TIKR.com5d ago
MarketWatch12d ago
MarketBeat48d agoEarnings
GuruFocus48d agoAnalyst
Yahoo Finance48d agoEarnings
MarketBeat48d ago
GuruFocus20d agoProduct
Mshale20d ago
Yahoo Finance20d ago
GuruFocus27d agoProduct
Loading more...